Core Insights - Hims & Hers Health, Inc. (HIMS) operates a consumer-first, digitally native healthcare platform that provides personalized care through telehealth, online pharmacy, and subscription services, focusing on chronic conditions like sexual health, hormone health, weight loss, dermatology, and mental health [1] Group 1: Business Model and Services - The company integrates licensed providers, proprietary technology, and cloud pharmacy infrastructure to support recurring treatment for various health conditions [1] - Recently, Hims & Hers has expanded into proactive and preventative care, launching Labs for data-driven testing and a multi-cancer early detection test in collaboration with GRAIL [2] - New offerings include menopause and perimenopause services on the Hers platform and exclusive oral testosterone treatments for men's health [2] Group 2: International Expansion - HIMS has entered Canada through the acquisition of Livewell and expanded its weight loss program to the U.K. [3] - The company announced plans to acquire Eucalyptus to enhance its presence in Europe and expand into Australia and Japan [3] Group 3: Market Performance and Valuation - Hims & Hers shares have decreased by 65.4% over the past year, underperforming the industry decline of 29.1% [6] - The forward 12-month price-to-sales (P/S) ratio for HIMS is 1.3X, significantly lower than the industry average of 3.8X and its five-year median of 2.7X [10] - The Zacks Consensus Estimate for HIMS' 2026 earnings per share suggests flat performance compared to 2025 [8]

Investor Presentation February 2025 Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this presentation that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding our future results of operations and financial position, including the underlying assumptions of any such project ...

Core Insights - GoodRx Holdings Inc. provides a platform for consumers to compare prescription drug prices and find discounts, competing with other healthcare technology companies [1] Financial Performance - Leerink Partners maintains an "Outperform" rating for GoodRx, indicating confidence in the company's potential to perform better than the market average, despite the stock price dropping to $1.99, reflecting an 18.78% decrease [2][6] - The recent Q4 2025 earnings call highlighted GoodRx's financial performance, focusing on earnings, revenue, and profit margins, which are essential for assessing the company's financial health and future prospects [3][6] Stock Performance - GoodRx's stock has experienced significant fluctuations, with a 52-week high of $5.81 and a low of $1.92, and the current market capitalization is approximately $675.3 million [4] - The stock price movement today ranged from a low of $1.92 to a high of $2.08, indicating market volatility, while the trading volume reached 11,549,681 shares, showing active investor interest [4][5]

Core Insights - The company is shifting its business model towards Pharma Manufacturer Solutions, rebranded as Pharma Direct, to capitalize on the trend of direct-to-consumer pharmaceutical commercialization [1] - The core Rx Marketplace is experiencing challenges due to the Rite Aid bankruptcy and reduced volumes in certain Integrated Savings Program partnerships, which is expected to impact revenues by approximately $35 million to $40 million in 2025 [1] - The strategic focus has transitioned to high-intent, condition-specific subscriptions in areas such as weight loss (GLP-1s), hair loss, and erectile dysfunction, where insurance coverage is often inadequate [1] Business Strategy - The company is utilizing its scale of nearly 300 million annual site visits to serve as a digital storefront for manufacturers implementing self-pay and discounted cash pricing strategies [1] - Direct contracting now encompasses 9 of the top 10 retail pharmacies, aimed at stabilizing retail margins and enhancing GoodRx's control over the pharmacy ecosystem [1] - The launch of Employer Direct is intended to fill gaps in traditional insurance by enabling employers to reduce the cost of specific brand medications like GLP-1s at the pharmacy counter [1]

Core Insights - The prescription experience is evolving to align with digital commerce trends, emphasizing clear pricing, fewer handoffs, and quicker fulfillment paths [1] - GoodRx's fourth-quarter earnings highlighted a shift towards self-service in healthcare, with executives noting pressures on customer base and subscription metrics leading to a decline in stock value [2] Digital Healthcare Trends - CEO Wendy Barnes indicated that affordability is now a primary consideration for consumers early in the prescription journey, requiring them to take a more active role in medication selection and payment [3] - GoodRx aims to develop tools that facilitate consumer comparisons and streamline processes, reducing the need for navigating disconnected manufacturer programs and pharmacy systems [4] Pharma Direct Strategy - GoodRx's Pharma Direct segment, previously known as Pharma Manufacturer Solutions, has over 100 brand self-pay programs, enhancing visibility through integration with TrumpRx [5] - The company reported that it accounted for nearly 20% of Wegovy pill self-pay fills in a specific week, demonstrating the effectiveness of its model [6] Rx Marketplace Developments - GoodRx expanded its Rx Marketplace, tripling its retail footprint and achieving an 83% increase in order volume quarter over quarter [8] Subscription and Employer Direct Initiatives - The company is focusing on condition-specific subscription offerings in areas like erectile dysfunction, hair loss, and weight loss, with early subscriber activations exceeding expectations [12] - Employer Direct is designed to integrate cash pricing with employer health plans, offering models that reduce out-of-pocket costs for specific medications [14] Financial Performance - GoodRx reported a decline in monthly active consumers to 5.3 million, a 14% decrease year-over-year, with subscription plans totaling 674,000 [16] - For the fourth quarter, revenue was $194.8 million, with adjusted EBITDA of $65 million, while prescription transactions revenue fell 6% year-over-year to $544 million [17] - The company projects revenue for 2026 between $750 million and $780 million, with adjusted EBITDA of at least $230 million, reflecting strategic investments in Pharma Direct and subscriptions [18]

Core Viewpoint - The shares of L'Air Liquide S.A. are expected to react positively following the company's latest earnings report, indicating a favorable outlook for investors [1]. Group 1: Company Performance - The latest earnings print for Air Liquide suggests strong performance, which may attract positive reactions from the market [1]. - The company is being analyzed by buy-side hedge professionals who focus on fundamental, income-oriented, long-term analysis across various sectors in developed markets [1]. Group 2: Analyst Position - The analyst has a beneficial long position in the shares of AIQUF and AIQUY, indicating confidence in the company's future performance [2].

Financial Data and Key Metrics Changes - For Q4 2025, revenue was $194.8 million, with Adjusted EBITDA at $65 million, leading to a full year revenue of $796.9 million, reflecting a 1% year-over-year increase [20] - Full year Adjusted EBITDA was $270.5 million, representing a 4% growth over 2024 [20] - Revenue from Pharma Direct increased to $151.4 million, up 41% year-over-year, driven by deeper sell-through at manufacturers and growth in consumer direct pricing [21] Business Line Data and Key Metrics Changes - Subscription revenue decreased by 3% year-over-year to $83.8 million, although early adoption of condition-specific subscriptions, particularly for weight loss, exceeded expectations [21] - The core marketplace remains foundational, but the company is increasingly focusing on Pharma Manufacturer Solutions as a key growth driver [9][11] Market Data and Key Metrics Changes - Monthly Active Consumers fell by 14% in 2025 compared to the previous year, but the company expects this number to stabilize from Q4 2025 through Q4 2026 [24] - The company reported nearly 25 million consumers and over 1 million healthcare professionals using its platform annually [11] Company Strategy and Development Direction - The company is evolving its business model to focus on Pharma Direct and Employer Direct offerings, which are seen as key growth opportunities [19][25] - The strategy aligns with the increasing consumer demand for direct-to-consumer healthcare solutions and the evolving dynamics of prescription access and pharmacy economics [7][25] Management's Comments on Operating Environment and Future Outlook - Management noted that affordability pressures and policy dynamics are reshaping access and pricing in healthcare, which plays to the company's strengths [7] - The company anticipates revenue pressure in 2026 due to strategic investments aimed at long-term durability, with Pharma Direct revenue expected to grow at least 30% year-over-year [23][24] Other Important Information - The company ended the year with $261.8 million in cash and approximately $80 million in unused capacity under its revolving credit facility [22] - The company repurchased approximately 48.9 million shares at an average price of $4.45 per share, totaling $217.4 million, signaling management's confidence in the company's future [22] Q&A Session Summary Question: Can you elaborate on the revenue guidance and unit economics? - Management explained that the decline in revenue is driven by the loss of significant revenue from Rite Aid and a shift of claims to Pharma Direct, which is reflected in the growth of point-of-sale programs [29][30] Question: How is the Pharma budget spending environment affecting new programs? - Management noted that spending has been pulled forward this year, with pharmaceutical manufacturers continuing to invest in direct-to-consumer programs [42][44] Question: What is the future of the legacy business amidst the focus on Pharma Direct? - Management confirmed that the core Rx Marketplace will remain foundational, but there is a strategic shift towards direct-to-consumer experiences as consumer preferences evolve [51][52] Question: How is the company addressing margin pressure? - Management indicated that while there is margin pressure, the focus is on stabilizing the underlying volume of scripts and renegotiating lower fees for long-term predictability [30][74] Question: What changes are being made to sales and marketing efforts in 2026? - Management stated that marketing spend will be redirected towards specific programs, with a focus on optimizing return on advertising spend [83][86]

Financial Data and Key Metrics Changes - For Q4 2025, revenue was $194.8 million, with Adjusted EBITDA at $65 million, leading to a full year revenue of $796.9 million, a 1% increase year-over-year [20] - Full year Adjusted EBITDA was $270.5 million, reflecting a 4% growth over 2024 [20] - Prescription transactions revenue declined by 6% year-over-year to $544 million, impacted by the Rite Aid bankruptcy and lower volume through an Integrated Savings Program partner [21] - Subscription revenue decreased by 3% year-over-year to $83.8 million, although early adoption of condition-specific subscriptions showed promise [21] - Revenue from Pharma Direct increased to $151.4 million, up 41% year-over-year, driven by deeper sell-through at manufacturers [21] Business Line Data and Key Metrics Changes - Pharma Manufacturer Solutions, now referred to as Pharma Direct, has become a key growth engine, with full year revenue up more than 40% in 2025 [9][21] - The prescription marketplace showed progress with order volume up 83% quarter-over-quarter, and direct contracts established with 9 of the top 10 retail pharmacies [15] - Condition-specific subscriptions, particularly for weight loss, have exceeded expectations, indicating strong potential for future revenue growth [16][21] Market Data and Key Metrics Changes - The healthcare landscape is shifting towards affordability and transparency, with consumers increasingly expecting direct-to-consumer access [7][10] - The growth of GLP-1 treatments for weight management has accelerated direct-to-consumer models, highlighting the need for transparent pricing and convenience [10][12] Company Strategy and Development Direction - The company is evolving its business model to focus on Pharma Manufacturer Solutions as a key growth driver, reflecting changes in prescription access and pharmacy economics [8][9] - GoodRx aims to enhance its core platform by accelerating subscriptions and deepening retail relationships, positioning itself for long-term growth despite near-term financial impacts [9][23] - The introduction of Employer Direct is seen as a natural extension of the GoodRx platform, addressing gaps in traditional insurance coverage [18][19] Management's Comments on Operating Environment and Future Outlook - Management noted that affordability pressures and policy dynamics are reshaping access and pricing in healthcare, which plays to GoodRx's strengths [7][25] - The company anticipates pressure on prescription transactions revenue in 2026 but expects Pharma Direct revenue to grow at least 30% year-over-year [23][24] - Management expressed confidence in the strategic direction and the ability to deliver value in a changing healthcare environment [25][26] Other Important Information - The company ended the year with $261.8 million in cash and approximately $80 million in unused capacity under its revolving credit facility [22] - Share repurchases totaled approximately 48.9 million shares at an average price of $4.45 per share, signaling management's confidence in the company's future [22] Q&A Session Summary Question: Can you elaborate on the revenue guidance and unit economics? - Management explained that the decline in prescription transaction revenue is due to the impact of Rite Aid's bankruptcy and a shift of claims to Pharma Direct, which is expected to stabilize over the long term [30][32] Question: How is the pharma budget spending environment affecting Pharma Direct programs? - Management noted that spending has been pulled forward this year, with pharmaceutical manufacturers continuing to invest in direct-to-consumer programs [42][44] Question: What is the future of the legacy business amidst the focus on Pharma Direct? - Management confirmed that the core Rx Marketplace will remain foundational, but there is a strategic shift towards direct-to-consumer experiences and partnerships with pharmaceutical manufacturers [51][52] Question: How is the company addressing margin pressure and price stability? - Management acknowledged that while there is margin pressure, the interrelation between Pharma Direct and the core business allows for shared brand economics, which is expected to stabilize pricing in the medium term [93]

Financial Data and Key Metrics Changes - For Q4 2025, revenue was $194.8 million, and Adjusted EBITDA was $65 million, leading to a full year revenue of $796.9 million, which is a 1% increase year-over-year [18] - Full year Adjusted EBITDA was $270.5 million, reflecting a 4% growth over 2024 [18] - Prescription transactions revenue declined by 6% year-over-year to $544 million, impacted by the Rite Aid bankruptcy and lower volume through an Integrated Savings Program partner [18][19] - Subscription revenue decreased by 3% year-over-year to $83.8 million, although early adoption of condition-specific subscriptions showed promise [19] - Revenue from Pharma Direct increased to $151.4 million, up 41% year-over-year, driven by deeper sell-through at manufacturers [20] Business Line Data and Key Metrics Changes - Pharma Manufacturer Solutions has become a key growth engine, with full year revenue up more than 40% in 2025 [7] - The company expanded its e-commerce ecosystem, tripling its retail footprint and achieving an 83% increase in order volume quarter-over-quarter [13] - Condition-specific subscriptions, particularly for weight loss, have shown strong early adoption, indicating potential for future revenue growth [19][14] Market Data and Key Metrics Changes - The healthcare landscape has seen intensified affordability pressures and evolving policy dynamics, which have reshaped access and pricing [5] - The growth of GLP-1 treatments for weight management has accelerated direct-to-consumer models, increasing consumer expectations for transparency and convenience [8] Company Strategy and Development Direction - The company is evolving its business model to focus more on Pharma Manufacturer Solutions as a key growth driver, reflecting changes in prescription access and pharmacy economics [6] - GoodRx is positioning itself as a digital storefront for self-pay and direct-to-consumer strategies, which are becoming central to prescription access [9] - The introduction of Employer Direct aims to help employers address gaps in traditional insurance coverage, expanding affordability and access [16] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's strategic direction, emphasizing the alignment with current healthcare trends and the importance of adapting to consumer-driven models [24] - The company anticipates pressure on prescription transactions revenue in 2026 but expects Pharma Direct revenue to grow at least 30% year-over-year [22][23] - Monthly active consumers fell by 14% in 2025, but management expects stabilization in 2026 [23] Other Important Information - The company ended the year with $261.8 million in cash and approximately $80 million in unused capacity under its revolving credit facility [21] - Share repurchases totaled $217.4 million, signaling management's confidence in the company's future [21] Q&A Session Summary Question: Can you elaborate on the revenue guidance and unit economics? - Management noted that the decline in prescription transaction revenue is due to the loss of significant revenue from Rite Aid and a shift of claims to Pharma Direct, which is expected to stabilize over time [28][29] Question: How is the pharma budget spending environment affecting Pharma Direct programs? - Management observed that spending has been pulled forward this year, with pharmaceutical manufacturers continuing to invest in direct-to-consumer programs [40][41] Question: What is the future of the legacy business amidst the focus on Pharma Direct? - Management confirmed that the core Rx Marketplace will remain foundational, but the focus is shifting towards direct-to-consumer experiences and partnerships with pharmaceutical manufacturers [48][50] Question: How will margin pressure manifest in the upcoming year? - Management indicated that while there may be margin pressure, investments in new offerings and a focus on long-term relationships with pharmacies will help stabilize the business [70][72]

Revenue and Income - Revenue for the year ended December 31, 2025, increased by 1% to $796.9 million from $792.3 million in 2024[348] - Net income rose to $30.4 million with a net income margin of 3.8%, compared to $16.4 million and 2.1% in the previous year[348] - Adjusted EBITDA for 2025 was $270.5 million, representing an Adjusted EBITDA Margin of 33.9%, up from $260.2 million and 32.8% in 2024[348] - Total revenue for the year ended December 31, 2025, was $796.9 million, a slight increase of $4.5 million or 0.6% from $792.3 million in 2024[1] - Operating income for 2025 was $87.5 million, compared to $65.8 million in 2024, indicating a year-over-year increase of $21.7 million[1] Consumer Metrics - Monthly Active Consumers decreased to 5.3 million in Q4 2025, down from 6.6 million in Q4 2024[352] - Subscription plans totaled 674,000 as of December 31, 2025, a decline from 684,000 in the same period of 2024[354] - The company is reassessing the Monthly Active Consumers metric to better align with growth and profitability measures[350] Revenue Streams - Prescription transactions revenue decreased by $33.5 million, or 6%, year-over-year, primarily due to a 14% decrease in Monthly Active Consumers[2] - Subscription revenue decreased by $2.8 million, or 3%, with 674 thousand subscription plans as of December 31, 2025, compared to 684 thousand in 2024[3] - Pharma direct revenue increased by $44.1 million, or 41%, year-over-year, driven by organic growth and expected to continue growing as a percentage of total revenue[4] Costs and Expenses - Total costs and operating expenses decreased to $709.4 million from $726.5 million, reflecting a reduction in sales and marketing expenses by $35.6 million, or 10%[1] Cash Flow and Investments - Net cash provided by operating activities was $167.9 million, a decrease of $16.0 million from $183.9 million in 2024[1] - Net cash used in investing activities increased by $49.6 million, primarily due to cash paid for business acquisitions in 2025[4] - As of December 31, 2025, the company had cash and cash equivalents of $261.8 million and $80.2 million available under its revolving credit facility[1] Financial Risks - The company has no foreign currency exposure as it only operates within the United States[397] - The company is exposed to interest rate risk due to debt arrangements with floating interest rates[398] - A hypothetical 100 basis point increase in interest rates would increase the company's interest expense by $5.0 million for the year ended December 31, 2025[398] - Interest income decreased by $12.3 million, or 53%, year-over-year, primarily due to lower average cash balances and interest rates[4] Market Conditions - The healthcare landscape is shifting towards greater transparency and direct-to-consumer access, presenting both opportunities and challenges for the company[345] - The company anticipates a total impact of $35.0 million to $40.0 million on prescription transactions revenue in 2025 due to external factors[346] - The company is increasing investments in its pharma direct and subscription offerings, expecting a near-term impact on revenue in 2026[347] - The company does not believe inflation has had a material effect on its business or financial condition[399] - If costs become subject to significant inflationary pressures, the company may struggle to offset these higher costs, potentially harming its financial condition[399]